Latest News and Press Releases
Want to stay updated on the latest news?
-
NJ-founded MetasTx is advancing an NCI-backed diagnostic and next-gen KIT inhibitor for high-risk prostate cancer, aiming for 2026 validation.
-
MetasTx has been awarded a NCI SBIR grant for its integrated diagnostic and therapeutic platform aimed at predicting and preventing prostate cancer.
-
FARMINGTON, Conn., and BOSTON, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- The Jackson Laboratory (JAX), a nonprofit biomedical research institution, and Seven Bridges, the leading biomedical data...